Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysine for severe aneurysmal subarachnoid hemorrhage after endovascular aneurysm treatment
ISRCTN16818128Phase 4Completed
- Sponsor
- Clinical Hospital Center Zagreb
- Start
- Sep 2021
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cerebrolysin in subarachnoid hemorrhage (SAH), sponsored by Clinical Hospital Center Zagreb. Primary endpoint: Functional outcome at 90 days. Started Sep 2021; status: completed.
02
Drugs
cerebrolysin
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ISRCTN16818128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16818128.